-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Moving forward and enlightening the future together! From January 6 to 8, 2023, the 3rd China Hematology Development Conference was grandly opened
.
THE CONFERENCE WAS HOSTED BY THE CHINESE ACADEMY OF MEDICAL SCIENCES AND PEKING UNION MEDICAL COLLEGE, THE HOSPITAL OF HEMATOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (INSTITUTE OF HEMATOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES), TIANJIN MEDICAL HEALTH RESEARCH INSTITUTE, CHINESE ACADEMY OF MEDICAL SCIENCES, STATE KEY LABORATORY OF EXPERIMENTAL HEMATOLOGY, NATIONAL CLINICAL RESEARCH CENTER FOR HEMATOLOGICAL DISEASES, CHINESE JOURNAL OF HEMATOLOGY, CELL ECOLOGY HAIHE LABORATORY, CHINESE PHYSIOLOGICAL SOCIETY HEMATOLOGY PROFESSIONAL COMMITTEE, TIANJIN SOCIETY OF HEMATOLOGY AND REGENERATIVE MEDICINE, BLOOD SCIENCE, With the theme of "Big Blood, Big Health, Great Health", Gobo Medical Group joined hands with more than 100 experts and scholars at home and abroad to discuss cutting-edge achievements in the field of hematology and seek the construction and vigorous development
of hematology.
On this occasion, Yimaitong sincerely invites Professor Liu Qiqi from the Institute of Hematology of Southern Medical University to be interviewed to share his insights
on the development of hematology in China.
Prof.
Liu Qiqi
Dean of the Institute of Hematology, Southern Medical University, Director of the Institute of Hematology
Director of the Department of Hematology, Professor, Chief Physician and Doctoral Supervisor of Southern Hospital
Member of the Asia-Pacific Society of Hematology
Vice Chairman of Hematology Branch of Chinese Medical Association
Leader of the Infectious Diseases Group of the Hematology Branch of the Chinese Medical Association
Vice President of Hematology Branch of Chinese Geriatrics Association
Vice Chairman of Cell Research and Therapy Branch of China Research Hospital Association
Member of the Standing Committee of the Hematologist Branch of the Chinese Medical Doctor Association
Chairman of Hematology Branch of Guangdong Medical Association and Vice Chairman of Cell Therapy Society
Chief expert of hematological oncology in Guangdong Province
Since graduating from university in 1983, he has been engaged in the diagnosis and treatment of hematological tumors and related basic research, and has been a visiting researcher at Tokyo Autonomous Medical University in Japan to conduct molecular biology research on leukemia
.
He has made great achievements in the fields of molecular pathogenesis of leukemia, tumor immunotherapy, hematopoietic stem cell transplantation and infection prevention and treatment in immunocompromised peopleHe has presided over 3 national key research and development programs, 3 863 programs, 10 national natural science including major/key projects and more than 20 provincial and ministerial projects
.
The relevant research achievements have won 1 second prize of National Science and Technology Progress Award, 3 first prizes of provincial and ministerial scientific and technological achievements and 5 second prizes
.
He has published more than 300 papers in core journals at home and abroad, including more than 200 papers in SCI journals such as Lancet Oncol/Haematol, JCO, PNAS, Blood and Leukemia
In recent years, new progress
has been made in the research of leukemia.
As one of the chairs of the leukemia thematic forum of the 3rd China Conference on the Development of Hematology, could you please talk about the current status of leukemia treatment in China and the future development direction?
Prof.
Liu Qiqi
In the past decade, leukemia treatment can be expressed in two words: "precise"
.
"Precision" includes precision diagnosis and precision treatment, and China has made more progress
in these two aspects.
The first major progress is reflected in the application of imaging, immunology and molecular biology in the diagnosis of leukemia, which has brought the diagnosis of leukemia in China into the era
of individualized diagnosis.
For different types of leukemia, different individuals, due to their different genetic backgrounds, we can give different diagnoses
.
The second major progress is reflected in precision treatment, which has entered the era
of precision treatment.
In the past, chronic myeloid leukemia (CML) required hematopoietic stem cell transplantation (HSCT) to be cured, but with the deepening of the understanding of CML and the emergence of specific targeted drugs, especially TKI targeted drugs, CML has gradually transformed into controllable chronic medical diseases
such as hypertension and diabetes.
In recent years, targeted drugs related to acute leukemia, especially acute myeloid leukemia (AML), have emerged in an endless stream, and the 5-year overall survival rate of acute lymphoblastic leukemia (ALL) or acute non-lymphoblastic leukemia (ALL) or acute non-lymphoblastic leukemia can reach more than 60% through targeted therapy combined with traditional chemotherapy and precision treatment strategies such as HSCT1,2
.
At present, the treatment level of leukemia in China has been in line with international standards, and even related treatment strategies and measures in some aspects are ahead of the international level
.
Yimaitong: Hematopoietic stem cell transplantation is an important treatment for leukemia, can you please talk about the application status of hematopoietic stem cell transplantation in the treatment of leukemia in the era of new drugs based on clinical experience?
Prof.
Liu Qiqi
HSCT is an important means of curing certain blood disorders, including leukemia, or even the only way
to bring cure to patients.
Although the era of new drugs has arrived, whether it is HSCT or targeted drugs, it is a part
of the treatment of leukemia.
The combined application of HSCT and targeted drugs can significantly improve the cure rate of leukemia, which is the current international and Chinese application status
of HSCT.
Yimaitong: Patients who receive hematopoietic stem cell transplantation are prone to co-infection, and need to pay great attention to it, in the high incidence period of new coronavirus infection, how do you think transplant patients should be managed to better prevent and treat infection?
Prof.
Liu Qiqi
During the period of high incidence of new coronavirus infection, how should we manage transplant patients and better prevent and treat infection? This is an important issue
facing both patients and doctors right now.
Because the epidemic control and opening up of other countries in the world is earlier than China, providing us with control experience, based on these international experiences and our understanding of the new coronavirus, the prevention and treatment of hematological cancer patients, especially HSCT patients, includes the following aspects: First, regarding the choice of transplantation timing, whether HSCT recipients or donors, strict new crown screening is required, and HSCT or donor stem cell donation
is usually not recommended during the infection period.
1-2 weeks after the virus turns negative, it should be safer
to transplant or donate in the current environment.
Second, regarding the management and control of HSCT patients, it is necessary to pay regular attention to the new coronavirus infection of patients, that is, regularly check nucleic acid or antigen
.
For patients infected with the new crown after HSCT, the treatment for the new crown infection is not significantly different from the general population, and some of the possible differences are that the transplanted patients involve more
organs than the immunocompetent people.
Recently, we conducted a statistic that about 60% of patients infected with the new crown after HSCT, the new coronavirus affected the lungs and related lesions, but their lesions tend to be mild and medium-sized, and the proportion of severe disease is low
.
It can be seen that patients who have undergone HSCT are not terrified of infection with the new crown, regular monitoring of nucleic acid, once the nucleic acid is found positive and some corresponding lung changes, timely give the patient the corresponding treatment, and there are fewer
patients who are transformed into severe disease.
Yimaitong: As a promising innovative therapy for hematological tumors, how is the progress of chimeric antigen receptor T (CAR-T) cells in the treatment of leukemia? In what ways can it continue to promote its application in the field of leukemia in the future?
Prof.
Liu Qiqi
Regarding the application of CAR-T in the treatment of hematological tumors, China is at the forefront
of the world.
The use of CAR-T, like chemotherapy and HSCT, is a means
of leukemia treatment.
At present, CAR-T is mainly used in patients with relapse, and it has not been concluded
that it can be used as a cure for leukemia.
How CAR-T can be effectively combined with traditional therapies, including targeted therapy, HSCT, and conventional chemotherapy, in the future to improve the long-term survival and cure rate of patients is an important direction
for future development.
Yimaitong: The 3rd China Hematology Development Conference ended successfully, its grand convening has effectively promoted academic exchanges in the field of hematology, and further promoted the construction and development of hematology in China.
Prof.
Liu Qiqi
The China Hematology Development Conference has been held for the third time this year, and I have participated in this conference from the first to the third session, and devoted myself to the construction of the
blood field.
The Chinese Conference on the Development of Hematology not only conducts academic exchanges in the field of hematology, but more importantly, the cross-integration of the field of hematology and other disciplines, which has played a great role in promoting the construction and development of hematology in China, and will provide great help for the diagnosis and treatment of hematological tumors in the future, and also plays a good role
in promoting the transformation of basic medicine to clinical medicine.
References:
1.
Hoelzer D, et al.
Ann Oncol.
2016 Sep; 27(suppl 5):v69-v82
2.
Heuser M, et al.
Ann Oncol.
2020 Jun; 31(6):697-712.
Disclaimer: This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.
Poke "Read Original" to watch the wonderful replay of the meeting
